Rosacea: New and Emerging Treatments
Rosacea: New and Emerging Treatments
复制标题
DOI：
10.1007/s40265-014-0281-x
复制
发表时间：
2014-09-01
期刊：
影响因子：
11.5
通讯作者：
Feldman, Steven R.
中科院分区：
文献类型：
--
作者：
Moustafa, Farah A.;Sandoval, Laura F.;Feldman, Steven R.
酒渣鼻是一种慢性炎症性皮肤病，对患者的生活质量产生负面影响。我们试图审查酒渣鼻的发病机制和新的治疗选择在其管理中的作用的重要方面。新的、新兴的治疗方法显示出了希望;然而，许多这些药物缺乏高质量的随机对照试验。酒石酸溴莫尼定是一种有效的新批准的治疗毛细血管扩张性酒渣鼻。局部应用羟甲唑啉有治疗毛细血管扩张性酒渣鼻的潜力，其疗效在病例报告和目前正在进行的随机对照试验中有描述。口服和外用伊维菌素均已被研究用于治疗丘疹脓疱性酒渣鼻，均显示出获益;然而，在随机对照试验中仅研究了外用伊维菌素1%乳膏。随着我们对酒渣鼻病因学的理解不断发展，我们对治疗干预的选择也将不断发展。需要进行进一步的研究来评估这些治疗的长期安全性和有效性。
Rosacea is a chronic inflammatory skin condition that negatively impacts patients' quality of life. We sought to review important aspects of the pathogenesis of rosacea and the role of new treatment options in its management. New, emerging treatments show promise; however, quality randomized controlled trials for many of these drugs are lacking. Brimonidine tartrate is an effective newly approved treatment for erythematotelangiectatic rosacea. Topical oxymetazoline has potential for the treatment of erythematotelangiectatic rosacea, with efficacy described in case reports and randomized controlled trials currently underway. Both oral and topical ivermectin have been studied for the treatment of papulopustular rosacea, both showing benefit; however, only topical ivermectin 1 % cream has been studied in randomized controlled trials. As our understanding of the etiology of rosacea continues to evolve, so will our options for therapeutic interventions. Further studies need to be performed to assess the long-term safety and efficacy of these treatments.